

References

I-9157

1. Spinraza prescribing information. Biogen. February 2023.
2. Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr Pulmonol.* 2019;54(2):179-185.
3. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med* 2017;377:1713-22.
4. Evrysdi prescribing information. Genentech, Inc. March 2023.
5. Zolgensma Prescribing Information. Novartis Gene Therapy, Inc. February 2023.
6. Arnold WA, Kassam D, Kissel JT. Spinal Muscular Atrophy: Diagnosis and Management in a New Therapeutic Era. *Muscle Nerve* 2015 Feb;51(2):157-167. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293319/>
7. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *N Engl J Med* 2018;378:625-635. doi: 10.1056/NEJMoa1710504
8. Keinath MC, Prior DE, Prior TW. (2021). Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance. *The application of clinical genetics*, 14, 11-25. <https://doi.org/10.2147/TACG.S239603>
9. Fang P, Li L, Zeng J, et al. Molecular Characterization and Copy Number of SMN1, SMN2 and NAIP in Chinese Patients with Spinal Muscular Atrophy and Unrelated Healthy Controls. *BMC Musculoskelet Disord.* 2015;16(1):11.
10. Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening. *J Neuromuscul Dis.* 2018;5(2):145-158.